News Medical on MSN5d
Gene therapy breakthrough offers hope for severe Dravet syndrome casesAAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...
Dravet syndrome and other developmental epileptic encephalopathies are rare but devastating conditions that cause a host of ...
A team of researchers has developed a new gene therapy for children with Dravet syndrome - a rare type of epilepsy in ...
Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights ...
Michigan Medicine researchers have developed a SCN1B gene therapy that restores brain function and survival in mice with ...
News Medical on MSN8d
Gene therapy shows promise in treating SCN1B-linked epileptic encephalopathiesDravet syndrome and other developmental epileptic encephalopathies are rare but devastating conditions that cause a host of symptoms in children, including seizures, intellectual disability, and even ...
The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential ...
The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...
Recent research takes aim at the a variant in gene SCN1B, which causes a severe form of developmental epileptic encephalopathy. Dravet syndrome and other developmental epileptic encephalopathies ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback